Shares in Danish drugmaker Novo Nordisk dropped as much as 5.3% on Friday, set for their biggest one-day fall since August 2022, after rival Amgen said it was encouraged by interim trial data on its experimental obesity drug. Novo Nordisk were last down 4.4% by 1022 GMT, having hit their lowest in two months earlier in the day. Amgen on Thursday said it was very encouraged after completing an interim analysis of its mid-stage study of experimental weight-loss drug MariTide, which, if approved, would compete Novo's Wegovy and Eli Lilly's Zepbound.
Jeremy Clarkson's farm manager is shown suffering a nasty injury in season three of the show - caused by equipment that was supposed to keep him safe.
The outcome measures for the upcoming study in adult-onset DM1 will be similar to those in the REACH-CDM Study.